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Introduction 
Pertussis is an endemic, highly communicable, vaccine-
preventable respiratory tract infection caused by the 
Gram-negative rod, Bordetella pertussis.  The highest 
burden is in the age groups with the least immunity 
(infants under 6 months of age and individuals over 10 
years old).  It is particularly problematic in young, pre-
vaccine infants and incompletely vaccinated children 
(Centers for Disease Control and Prevention (CDC), 
2010a). 
Editor’s Note: Dr. Golding spent part of his preventive
medicine residency with the Division of Acute Disease 
Epidemiology, where he participated in outbreak response 
and focused on provider education for pertussis, especially
in adult patients. This article is a product of that work.
Pertussis is one of the 10 most common causes of death 
in childhood and it remains in fifth place among the 
leading etiologies of vaccine-preventable deaths in 
children around the world.  The impact of this disease is 
considerable in North America, Latin America, Europe, 
and other parts of the world (Ulloa-Gutierrez, 2009).  
A total of 20 to 40 million cases of pertussis are reported 
annually in the world, 90% of which occur in developing 
countries; pertussis results in 200,000 to 400,000 deaths 
per year, most of which are reported in young infants 
(Leung, Robson, & Davies, 2007).  However, under-
diagnosis and under-reporting mean that the true burden 
of pertussis is still underestimated (Cherry, 2010; CDC, 
2010a; Leung, et al., 2007; Wood & McIntyre, 2008). 
(Continued on page 3)
As of January 1, 2011, there is  one new condition reportable to SC DHEC by 
laboratories, Carbapenem-resistant enterobacteriaceae (CRE).  Additionally, reporting 
criteria have been expanded, clarified, or updated for several conditions, as indicated 
below. The List of Reportable Conditions is available from the SC DHEC website: 
http://www.scdhec.gov/health/disease/reportables.htm. 
CRE: Added to list for Laboratory Reporting
Starting in 2011, infection with Carbapenem-resistant enterobacteriaceae 
(CRE) is routinely reportable (within 7 days) to DHEC by laboratories.  Clinicians are 
(Continued on page 2)
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(Continued from page 1)
advised to consider carbapenem-resistant 
enterobacteriaceae (CRE) in their differential diagnosis of 
difficult to treat infections, especially in intensive-care 
unit patients. 
Background: Infection with carbapenem-resistant 
enterobacteriaceae (CRE) is increasingly becoming a 
health-care challenge.  Up to this point, CRE has caused 
healthcare-associated infections, and usually affects those 
with compromised immune function.  The most common 
type of CRE is the Klebsiella pneumonia carbapenemase 
(KPC) -producing organism. KPC-producing 
enterobacteriaceae are widespread in the US and other 
countries. 
From January to June 2010, three enterobacteriaceae 
isolates carrying the New Delhi metallo-beta-lactamase 
(NDM-1) resistance mechanism were identified from three 
US states at the CDC antimicrobial susceptibility 
laboratory.  While uncommon in the US, organisms 
carrying this mechanism of resistance have been seen 
here and in the United Kingdom, especially among 
patients who had received medical care in India and 
Pakistan.  Similarly, all three US isolates were from 
patients who had recently received recent medical care in 
India. While KPC production has most commonly been 
seen in Klebsiella pneumonia, it has also been reported in 
other pathogens, such as Escherichia coli, Salmonella
spp., Serratia spp., Pseudomonas spp., and others.
Dengue: Submit Confirmatory Specimens
Dengue (Flavivirus) has been added to the list of 
conditions for which isolates, broths, and serum are to be 
submitted to the DHEC Bureau of Laboratories for 
confirmatory testing or genotyping. 
HIV/AIDS: Report positive EIA tests
Positive EIA has been added to the list of HIV detection 
tests that must be reported to DHEC. 
Influenza, Pediatric Deaths reportable in 24 
hours 
Confirmed deaths from influenza in persons younger than 
18 years of age are now urgently reportable to DHEC
(within 24 hours.) For these cases, influenza is confirmed 
by culture, RT-PCR, DFA, IFA, influenza rapid test, or 
autopsy results consistent with influenza 
Outbreaks: Specimens may be requested
In an outbreak, defined as an excess number of cases or 
syndromes over the expected occurrence of disease 
within a geographic area, population group, or healthcare 
facility, clinical specimens may be requested from 
patients. Healthcare providers may be asked to assist 
with procurement of specimens. 
Rabies Post-exposure Prophylaxis, Animal 
Bite Management Guidelines
The print and web-based versions of the List of 
Reportable Conditions point providers to DHEC’s Guide 
to Managing Animal Exposures and Rabies 
Postexposure Prophylaxis.  This guidance includes
phone numbers for during work hours and after-hours/ 
weekend medical and environmental health consultation. 
The Guide can be accessed from the Home Page of the 
DHEC website (www.scdhec.gov/) or directly from this 
link: http://www.scdhec.gov/health/envhlth/ 
general sanitation/rabies-resources-healthcare­
providers.htm. 
Copies of Reportables Posters
Contact your Regional Public Health Department for 
Disease Reporting Cards and for printed copies of the 
2011 List of Reportable Conditions and Laboratory List of 
Reportable Conditions.  Regional Office Contact 
information is available from http://www.scdhec.gov/ 
health/disease/reportables.htm, where you can also 
download and print PDF copies of these lists. 
Electronic Reporting 
Call 1-800-917-2093 to learn more about electronic 
disease reporting, or navigate to http://www.scdhec.gov/ 
health/disease/chess/index.htm for information about 
CHESS, South Carolina’s electronic disease reporting 
system. 
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Figure 1: US Pertussis Case Trends (1922-2003) From Pertussis — Not Just 
for Kids (Hewlett & Edwards, 2005)
(Continued from page 1)
Pertussis in the US: By the Numbers 
• 	 Since the early 1990s, the US 
disease incidence in adults and 
adolescents has been on the 
increase. 
• 	 In 2004, the number of US cases 
doubled compared with previous 
years. In 2005, adolescents and 
adults contributed the greatest 
number of cases -- 60% (Leekha, 
Thompson, & Sampathkumar, 2009). 
• 	 In 2009, there were 16,858 cases in 
the US. 
• 	 In 2010, there were 21,291 cases 
reported through Week 52 (MMWR). 
• 	 Among children, preliminary US case 
rates for 2010 were estimated at 
49/100,000 in infants less than 12 months of age 
and 8/100,000 in children 1-4 years of age.  This
demonstrates a high risk in young pre-vaccination 
Figure 2: Confirmed and Probable Pertussis Cases in SC, 2004-2010.  
(SC DHEC, Division of Acute Disease Epidemiology, 2011).  
babies and incompletely vaccinated young 
children (CDC, unpublished data). 
Pertussis in South Carolina
In 2010, South Carolina had 391 
confirmed and probable pertussis cases 
reported as of mid-December.  This
demonstrates the cyclical nature of 
pertussis incidence for that is also seen 
nationally  (South Carolina Department 
of Health and Environmental Control (SC
DHEC, 2010)  The putative reasons for 
the state and national increases in total
pertussis incidence as well as the 
increasing adolescent and adult 
proportions are enumerated below.
Sc data indicate that total disease rates 
are rising.  They also demonstrate a 
considerable proportion of cases in “non­
children” (i.e., adolescents and adults), 
as demonstrated in Figure 3 (page 4) 
Pertussis Epidemiology
The only known reservoir for B. pertussis
is human adolescents and adults with 
waning humoral and cell-mediated 
immunity from childhood vaccination or
(Continued on page 4)
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(Continued from page 3)
disease. As both vaccine and naturally acquired immunity 
decrease over time, young infants with inadequate 
immunity and small airways are at very high risk from
exposure to these newly susceptible adolescents and
adults.  
Pertussis tends to become epidemic every 2-5 years; a 
trend unchanged from the years before vaccine 
introduction.  Outbreaks occur throughout the year in the 
US (Cherry, 2010; CDC, 2010b).  Pertussis vaccination 
has reduced the case incidence in peak years by more
than 95%.  
Pertussis outbreaks are not uncommon.  California 
reported 8,383 pertussis cases in 2010 (21.4 
cases/100,000), the highest number since 9,394 cases 
were reported in 1947, and the highest incidence since 
1958, when 26.0 cases/100,000 were reported.  There 
were 10 infant deaths from pertussis in California in 2010, 
nine of whom were unvaccinated infants under 2 months 
of age (California Department of Public Health, 
Immunization Branch, 2011).  In Michigan, an increase 
was noted in mid- 2008 and it has continued to date.  
This has compounded a long-term increase in cases since 
the early 1990s.  Moreover, as of October 31, there were 
902 cases reported for 2010.  By comparison, in 2008 and 
(Continued on page 6)
Figure 3: Age-Specific Cases and Case Rates.  (SC DHEC, Division of Acute Disease Epidemiology, 2010).  2010 case numbers and 
rates were markedly increased over those from 2004-2009.  The attack rates are much higher in young infants with little to no immunity 
and very small airways.  The only known reservoir is adolescents and adults with waning immunity.  Pertussis is not only a childhood 
disease; as adolescent and adult immunity wane, they may become infected and, in turn, infect young babies without immunity.
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Figure 4: The Epidemiological Cycles of Pertussis before and after the Vaccine Introduction.  (From Hew­
lett & Edwards, 2005) 
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(Continued from page 4)	 • Mutations in B. pertussis, 
2009, 315 and 902 cases were reported, respectively for 
the complete year (CDC, 2010b). 
The Impact of Pertussis Vaccine
In the pre-vaccine era, pertussis was one of the most
common and contagious childhood respiratory infectious 
diseases and a major cause of childhood morbidity and 
mortality in the United States.  The whole-cell pertussis 
vaccine became available in the 1940s.  At the time of 
vaccine introduction, the infection was universally present 
with cyclic peaks every 2–5 years.  Cases were seen 
primarily in children under 10 (93% of cases).  Ten 
percent of the cases involved infants.  The introduction of 
the diphtheria, tetanus toxoid and whole cell pertussis 
(DTP) vaccines changed the rate of reported pertussis 
from 157 per 100,000 in the prevaccine era to <1 per
100,000 in the 1970s.  In the 1970s, 50% of the reported 
cases were observed in infants and few cases were noted 
in adults. However, now about 65% of reported cases 
occur in persons over 10 years of age (Cherry, 2010).  
“Vaccine Era” Epidemiology 
Since widespread use of pertussis vaccine began, 
incidence has decreased more than 80% compared with 
the pre-vaccine era.  However, despite the widespread 
availability of an effective vaccine for decades, there has 
been a significant resurgence in pertussis cases, 
beginning in the 1980s. This resurgence has been 
greatest among 10 to 19 year olds and infants younger 
than 6 months of age, (Cherry, 2006).  Moreover, from 
2001 to 2003, persons >10 years of age accounted for 
56% of reported cases, more than double the 24% they 
accounted for from 1990 to 1993.  In 2005, the incidence 
of reported pertussis was 8.6 per 100,000 persons (CDC, 
2008a). In 2008, more than 13,000 cases of pertussis 
were reported—and many more cases go unreported. 
Despite this trend in older persons, incidence remains 
highest in young infants. In 2005, most (38 of 39) 
pertussis-related deaths reported to CDC were among 
infants aged <6 months, who were too young to have
received three doses of DTaP vaccine.  
Many industrialized countries with long established 
immunization programs are currently experiencing 
resurgences of pertussis despite universal vaccination
with high uptake. The posited etiologies of this 
phenomenon are many including:  
• 	 Lessened potency of acellular vaccine, 
• 	 Better and quicker laboratory identification, 
especially polymerase chain reaction (PCR), 
• 	 Greater clinical awareness of pertussis in the 
medical and public health communities, including 
increased surveillance and reporting, and  
• 	 The increased proportion of adolescents and 
adults cases over the last quarter-century.  As 
adolescents’ vaccine-induced immunity wanes, 
their disease susceptibly increased.  (Cherry, 
2010). 
Despite increased incidence of disease and increased 
awareness of pertussis, CDC believes that much of 
pertussis disease still goes unrecognized and unreported 
(Cherry, 2010; CDC, 2010a).  This may be associated
with the wide variation in presenting 
symptomatology associated with disease in a 
population experiencing age-related gradual decrease of 
disease protection (CDC, 2010a; Leung, et al., 2007; 
Wirsing von König, Halperin, Rifflemann, & Guiso, 2002; 
Wood & McIntyre, 2008). 
It is axiomatic that effective prevention and treatment of 
pertussis depends on the health care community’s 
knowledge of the epidemiology and pathobiology of the 
disease. All too frequently, however, pertussis is 
not even “on the radar screen” of medical 
providers and it is often not part of the differential 
diagnosis of prolonged and/or atypical cough of
adolescents and adults.  This under-diagnosis and
under-appreciation of pertussis in adolescents and adults 
is a major impediment to disease treatment and control 
(Rossi-Foulkes, et al., 2010), since adolescent and adult 
cases do not necessarily fit the classic “whooping cough” 
case picture.  In fact, the distinct clinical phases of the 
disease and the characteristic whoop occur infrequently in 
adolescent and adults patients.  (Leekha, et al., 2007).  
Overall, signs and symptoms in 
adolescents and adults are less 
typical than the “classic” presentation 
seen in unvaccinated children
It may be of value to compare the “Classic” presentation 
of pertussis, described in the pediatric, non-immune 
population, with the atypical symptomatology observed in 
older, partially/formerly immune patients.  
(Continued on page 7)
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“Classic” B. pertussis infection in the non-immune 
is characterized by 3 phases: 
• 	 Catarrhal stage 
• 	 Usually 1 to 2 weeks in length, signs, and 
symptoms non-specific making diagnosis difficult.  
May seem to be a viral URI with generalized 
malaise, rhinorrhea, and mild cough. 
• 	 Low-grade fever may be present, but
 
significant fever is atypical.

• 	 Early excessive lacrimation and conjunctival 
injection are seen. 
• 	 Recent sick contacts: the incubation period for B.
pertussis is relatively long (7-10 days) compared 
with most viral URIs (1-3 days).
• 	 Exposure to a person with a cough illness 1 to 2 
weeks prior to symptoms-onset (especially a high 
-risk contact, e.g., one working with children or 
living in a low vaccine coverage area.)  
• 	 Paroxysmal stage 
• 	 Follows the catarrhal stage with hallmark 

coughing spells. 

• 	 A series of coughs during a single expiration; 
often occur in groups throughout the day and 
night, feel and look well between paroxysms. 
• 	 Causes low lung volumes, prompting vigorous 
inspiration that may result in a whoop, more 
often heard infants and children with small 
airways.  
• 	 Very dramatic and not soon forgotten cough 
presentation.  (See ww.immunizationed.org for 
audio and video of examples of infants and 
children with the infection.)  Other typical 
symptoms include post-tussive emesis or syncope 
(The Group on Immunization Education of the 
Society of Teachers of Family Medicine, 2010.) 
• 	 Convalescent stage
• 	 After about 2 to 3 months, there is a gradual 
transition to the convalescent phase. 
• 	 Persistent but decreased frequency/ severity of 
cough. 
• 	 It is reported that the traditional Chinese 
medicine calls pertussis the "the 100-day
cough" (Cornia, Hersh, Lipsky, Newman, & 
Gonzales, 2010; Gregory, 2006). 
“Atypical Pertussis” Diagnostic Considerations 
for the Non-Child Patient
Pertussis symptoms in previously immunized or 
infected adolescents and adults are more variable 
and often atypical.  Persistent, uncharacteristic 
cough may be the sole presenting sign of the 
disease (Cornia, et al., 2010; Dworkin, 2005; Gregory, 
2006; Hewlett & Edwards, 2005).  
All too frequently, pertussis is not 
even “on the radar screen” of medical 
providers and it is often not part of 
the differential diagnosis of 
prolonged and/or atypical cough of 
adolescents and adults.
Studies have shown that around 12 to 32 % of 
adolescents and adults with a prolonged cough (>6 days) 
have serologic evidence of B. pertussis infection and that 
the symptoms and complications due to pertussis may be 
very different from those observed in infants and 
children. Scratchy throat, trouble swallowing and other 
pharyngeal complaints occur in ~30% of adults with 
pertussis. In addition, diaphoretic episodes are seen in 
40 to 50 % of cases >30 years of age and about 70 to 
99% of adolescents and adults reported paroxysmal 
cough (Hewlett & Edwards, 2005).  Cough lasts at least 3 
weeks in ~80 % of adults and adolescents, and 3 months
or more in ~30 % of non-child patients.  Post-tussive
emesis is common but most adult patients do not whoop 
at the end of the paroxysm.   
Overall, signs and symptoms in adolescents and 
adults are less typical than the “classic” 
presentation seen in unvaccinated children
(Dworkin, 2005; Gregory, 2006; Hewlett & Edwards, 
2005; Wirsing von König, 2002). 
Disease Complications in Non-Child Patients
Complications of pertussis are numerous, and similar in 
adolescents and adults. Pneumonia is most common (2.1 
to 3.5 %); seizures (0.3 to 0.6 %) and/or encephalopathy 
(0.1 %) are most severe sequellae among non-child 
(Continued on page 8)
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(Continued from page 7)
patients. Other complications include cough-induced
urinary incontinence in older patients, herniated discs, rib 
fracture, hernia, non-specific back pain, the sudden onset 
of hearing loss, angina, and even carotid-artery 
dissection.  The cough may severely disturb sleep and/or 
cause choking.  Other pertinent clinical findings may 
include diaphoresis and syncope.  Finally, infectious 
complications such as sinusitis and otitis media are 
common (Gregory, 2006; Hewlett & Edwards, 2005). 
Missed Diagnoses 
Clinicians frequently do not consider pertussis in 
adolescents and adults with atypical or prolonged cough, 
however.  The relatively long incubation period, non­
specific symptomatology, difficulty culturing the 
organism, and the historic lack of accepted diagnostic 
testing have all been problematic in this regard (Cornia, 
et al., 2010). 
The previously noted 12-32% etiologic proportion of 
prolonged cough illnesses being attributable to B.
pertussis represents a reasonable pretest probability 
estimate for adolescents and adults.  Serologic studies 
suggest that the rate of B. pertussis infection in these 
groups is 2.0% per year. The rate of cough illnesses 
caused by B. pertussis in adolescents and adults has been 
estimated to be between 370 and 1500 cases per 
100,000 population.  The bottom line is that there are 
between 800 000 and 3.3 million cases per year in the 
United States (Cornia, et al., 2010; Cherry, 2006).   
Diagnosis of pertussis in adolescents and adults becomes 
even more difficult with the presence of residual 
immunity from prior vaccination.  This can greatly modify 
the clinical presentation of pertussis in adolescents and 
adults. The patient may look and feel completely well 
between bouts of cough.  Moreover, the diagnostic 
possibility of pertussis may be overlooked in non-child
patients due to the mistaken perceptions that pertussis is 
solely a disease of infancy and childhood, that has been 
totally controlled by routine pediatric immunization, and 
that this immunity is life-long (Dworkin, 2005; Gregory, 
2006; Hewlett & Edwards, 2005). 
The provider must take a systematic approach to the 
diagnosis of adolescent and adult cough and develop a 
thoughtful and through differential diagnosis.  
Determining the cough duration is a useful first 
step in formulating an approach. Coughs may be 
classified as: 
• 	 Acute (<3 weeks): An acute cough may be 
seen with serious non-infectious and infectious 
processes such as congestive heart failure, 
pneumonias of various etiologies, lung cancer, or 
pulmonary embolism. Acute cough is mostly 
commonly self-limited, viral upper respiratory 
tract infection (rhinovirus, etc). 
• 	 Subacute (3-8 weeks): A cough lasting 3-8 
weeks may represent persistence of an acute viral 
or bacterial respiratory infection or a lower 
respiratory tract infection. 
• 	 If a respiratory infection did not precede the 
cough, evaluation for chronic cough. 
• 	 In smokers, in patients taking angiotensin-
converting enzyme (ACE) inhibitors, the first 
step would be to stop. 
• 	 Chronic (> 8 weeks): If the cough continues, it 
may be most commonly caused by 
gastroesophageal reflux disease (GERD), asthma
or postnasal drip/chronic sinusitis.  Of course, TB 
must be considered in chronic cough, as must non 
-asthmatic eosinophilic bronchitis, defined by 
cough accompanied by sputum showing 
eosinophils without asthma. 
In addition to these well-known causes of 
subacute or persistent non-child cough, providers 
should think of pertussis when faced with an 
adolescent or adult patient with subacute and 
chronic cough.  (Cornia, et al., 2010)  
Case Definitions
A case definition is epidemiologically important.  
However, not meeting a strict case definition 
should not hinder timely treatment of sick patients 
with appropriate symptomatology. The WHO and 
CDC case definitions for pertussis use different clinical
criteria: the WHO definition is more appropriate for 
severe disease in non-vaccinated children with three or 
more weeks of paroxysmal coughing.  It is more specific 
rather than sensitive.  The CDC clinical case definition 
was formulated for disease surveillance.  Here, cough 
duration is at least 2 weeks with either paroxysms or 
whooping.  For adolescent and adult pertussis, the CDC 
definition is more appropriate.  Most adult and adolescent 
(Continued on page 9)
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Figure 5: A Pertussis Time-Line (CDC, 2010a)
(Continued from page 8)
cases would fit the latter definition.  As detailed later, 
culture and polymerase chain reaction (PCR) is helpful in 
establishing the diagnosis if a specimen can be obtained 
early in the course of the illness.  Serology, although not 
meeting a surveillance case definition, can be useful 
when the diagnosis is not suspected until a later stage.  
(Wood & McIntyre, 2008)  
Patients are most infective during the catarrhal stage of 
the disease as well as the initial two weeks of cough (see 
the time line above).  Due to the perceived mildness and 
non-specific nature of the signs and symptoms during
these early stages of the disease, the firm diagnosis of 
pertussis has usually not been made during this period of 
maximum communicability.  90 to 100 % of susceptible 
non-immune household contacts exposed to a 
symptomatic individual during this period will develop the 
disease.  In addition, the attack rate in household 
contacts older than 15 years has been reported to be as 
high as 80-85 %  (Tan, 2005).  
Treatment and Post-Exposure Prophylaxis 
Treatment with a macrolide antibiotic is recommended for 
affected individuals; macrolide antibiotics are also 
recommended for post-exposure prophylaxis of all 
household and other close contacts.  A 5-day course of 
Azithromycin, for treatment and prophylaxis, is well 
tolerated and safe (CDC, 2010a; Leung, et al., 2007; 
Wirsing von König, et al., 2002; Wood & McIntyre, 2008).  
(Continued on page 10)
The SC Board of Medical Examiners, at its August 2010 meeting, voted to approve the 
following policy: 
Post-Exposure Prophylaxis (PEP) is often recommended by numerous medical professional and public 
health organizations (notably the Centers for Disease Control [CDC], the American Public Health 
Association/ World Health Organization’s Control of Communicable Diseases Manual, the American 
Academy of Pediatrics Red Book, or the South Carolina Department of Health and Environmental 
Control [DHEC]) to protect specific persons from acquiring contagious/ communicable diseases from 
close contact with infected persons. The SC Board examiners approves and recommends the 
prescribing of PEP in accordance with the most current established guidelines as published by these 
organizations, even in the absence of a previously-established patient-physician relationship 
(emphasis added). 
http://www.llr.state.sc.us/POL/Medical/PDF/PostExposureProphylaxis.pdf
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(Continued from page 9)	 agonists, steroids or immunoglobulins have not been 
proven to be helpful (Gregory, 2006).    
Treatment should begin prior to receipt of laboratory The SC Board of Medical Examiners strongly 
confirmation in highly suspicious and/or very ill clinical encourages providers to prescribe post-exposure 
cases.  A PCR and culture from an appropriately obtained prophylaxis to contacts of patients, even in the 
nasopharyngeal swab should be sent to the reference absence of an established provider-patient 
laboratory before commencing said therapy.  Adjunct relationship. (See box, page 9 )
treatments with antihistamines, decongestants, β­
(Continued on page 11)
Guidelines for Pertussis-Containing Vaccines
DTaP:  (Modified from CDC, 2010a; SC DHEC, 2010)
1. 	 DTaP ages 2, 4, 6 months (minimum start age: 6 weeks);  
2. 	4th DTaP dose as early as age 12 months, provided at least 6 months have elapsed since the third dose; 
usually given between 15-18 months of age;  
3. 	 Final DTaP dose in the series is given at age 4 through 6 years. 
Tdap§: (CDC, 2011, p. 14) 
General Recommendations
• 	 For routine use, adolescents aged 11 through 18 years who have completed the recommended childhood 
diphtheria and tetanus toxoids and pertussis/diphtheria and tetanus toxoids and acellular pertussis (DTP/DTaP) 
vaccination series, and adults aged 19 through 64 years should receive a single dose of Tdap.  Adolescents should 
preferably receive Tdap at the 11 to 12 year-old preventive health-care visit. 
Timing of Tdap
• 	 Can be administered regardless of interval since the last tetanus- or diphtheria-toxoid containing vaccine. 
Adults Aged 65 years and Older¶ 
• 	 Those who have or anticipate having close contact with an infant aged less than 12 months should receive a 
single dose of Tdap.
• 	 Other adults ages 65 years and older may be given a single dose of Tdap. 
Children Aged 7 Through 10 Years
• 	 Those not fully vaccinated against pertussis* and for whom no contraindication to pertussis vaccine exists should 
receive a single dose of Tdap.
• 	 Those never vaccinated against tetanus, diphtheria, or pertussis or who have unknown vaccination status should 
receive a series of three vaccinations containing tetanus and diphtheria toxoids. The first of these three doses 
should be Tdap.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
§ As of this time, however, neither the Sanofi Aventis nor the GlaxoSmithKline Tdap booster is approved for children aged 7 to 10 
or adults 64 or older. Both GSK and Sanofi have stated they intend to seek approval from the FDA to broaden the age ranges 
for Tdap to include both groups.  Until then, providers can give the vaccine on an off-label basis (Steenhuysen, 2010). 
* 	 Fully vaccinated is defined as 5 doses of DTaP or 4 doses of DTaP if the fourth dose was administered on or after the fourth
birthday. 
¶ 	 Further recommendations on the use of both Tdap vaccines in adults aged 65 years and older will be forthcoming should one or 
more Tdap products be licensed for use in this age group. (CDC, 2011). 
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(Continued from page 10)
Vaccination 
With pertussis thought of as a childhood disease, 
physicians may overlook opportunities to provide 
pertussis vaccinations to adolescents and adults.  
Emblematic of this are the results of a 2008 survey of
Illinois physicians.  Although the CDC Advisory Committee 
on Immunization Practices (ACIP) has recommended the 
pertussis booster vaccination for all adolescents and 
adults up the 64 years of age since 2006, the survey 
showed that Tdap coverage in adolescents 13-17 years 
was 40.8%, compared with 72.2% for Td vaccine (Rossi-
Foulkes, et al., 2010). 
In addition, review of medical board preparation materials 
extent during this same period of time demonstrated 
gaps in pertussis-related educational coverage.  A major 
effort aimed at increasing adult provider appreciation of 
the clinical impact of adolescent and adult pertussis is
needed. Baseline and follow-up data quantifying 
physician knowledge may help target educational efforts 
and facilitate pertussis vaccination and reporting (Rossi-
Foulkes, et al., 2010)  
Two adolescent and adult formulations of acellular 
pertussis vaccine (Tdap) are licensed in North America 
and Europe.  Both are combined with an adult 
formulation of diphtheria and tetanus toxoids.  In the US, 
Adacel ® (Sanofi Pasteur, Toronto, Ontario, Canada) is
licensed for use in individuals aged 11 to 64 while 
Boostrix ® (GlaxoSmithKline Biologicals, Rixensart,
Belgium) is licensed for use in the 10 to 64 age range.  
These vaccines are safe, immunogenic, and well tolerated 
(Leung, et al., 2007). 
Three studies conducted with Canadian children and 
adolescents evaluated the safety of Tdap (Adacel ®) at 
an interval shorter than 5 years after Td or after pediatric 
DTP or DTaP (David, Hemsley, Pasquali, Larke, Buxton, & 
Lior, 2005; Halperin, et al., 2006; Public Health Agency of 
Canada, 2005).  The largest was an open-label study of 
7,001 students aged 7-19 years.  Rates of local reactions 
were not increased among students who had received the 
most recent of 5 pediatric DTP or DTaP doses, or a Td 
dose, >2 years before Tdap, compared with >10 years 
before Tdap (Halperin, et al., 2006).  The other Canadian 
studies demonstrated similar safety when Tdap was 
administered at an interval of <5 years after the previous 
tetanus toxoid and diphtheria toxoid-containing vaccine
(David, et al., 2005; Public Health Agency of Canada, 
2005). 
Vaccine Strategies and Issues
Caregivers for young infants (parents, siblings, 
other family, and babysitters) and health care 
personal are very high priority vaccine candidates. 
Other strategies under consideration include  
a. the substitution of Tdap for Td for tetanus 

prophylaxis during wound management;
 
b. “cocooning” the pre-vaccine infant via vaccination of 
the mother immediately postpartum or in the 2  or 
3rd trimester
c. 	vaccination of all infant caregivers (Cherry, 2010).  
CDC researchers estimate that 6-8% of pertussis 
cases are transmitted from grandparents to children.  
Obviously, many grandparents are over 64 with poor
pertussis immunity; and 
d. As a future strategy, vaccination of newborns with 
monovalent or combined acellular pertussis vaccine 
between 2-5 days of age.  A candidate vaccine has 
shown promise but it is not on the market at the 
present (Ulloa-Gutierrez, 2009).  
To eliminate the disease and the circulation of the 
bacterium, however, universal childhood DTaP and 
decennial Tdap immunization starting in preadolescence 
and continuing through adulthood must be the standard 
of care.  Adults and adolescents should obtain a Tdap 
booster as per current ACIP recommendations.  All 
adolescents and adults need the vaccine, even if they 
have had a Td booster.  SC DHEC and the CDC 
recommend substituting Tdap for the next Td for all 
adolescents and adults. In addition, they recommend a 
“catch-up” dose now unless the last Td was within the 
last 2 years (CDC, 2010a; SC DHEC, 2010).  In the 
future, however, it is very likely that the Tdap will 
replace the decadal Td for maintenance of tetanus 
and pertussis immunity outside of childhood 
(Mertsola, et al., 2010).  
Health perceptions and beliefs are also very important in 
control of pertussis.  Studies by Omer, et al (2006; also 
Omer, Salmon, Orenstein, deHart, & Halsey, 2009) found 
that in states where non-medical exemptions were easier 
to obtain, the mean annual incidence of pertussis was 
almost twice that of states that made it more difficult.  
Summary 
Pertussis should never be thought of as a “zebra” 
in the non-child patient population. It deserves 
consideration in the differential diagnosis of all 
(Continued on page 12)
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adolescents and adults presenting with atypical, 
subacute, or chronic cough.  Increased awareness of 
pertussis among providers treating non-child patients is of 
the utmost importance in the ongoing battle against 
pertussis (Dworkin, 2005). 
To reiterate, adults and adolescents with waning natural 
or vaccine-acquired immunity are the only known 
reservoir for B. pertussis. These infections may be, in
turn, transmitted to pre-vaccine (<2 months of age) and/ 
or incompletely vaccinated infants (incomplete DTaP 
primary series), among whom significant morbidity and 
mortality may occur.  Moreover, reporting this disease to 
the local health department is critical to its control 
because both cases and their close contacts should 
receive post-exposure macrolide prophylaxis (Dworkin, 
2005; Gregory, 2006; Hewlett & Edwards, 2005). 
It bears saying again: all health care providers, not 
just pediatricians, need to be aware of the 
epidemiology and risk profile of this endemic 
respiratory agent. It is incumbent on all clinicians 
to consider pertussis in all non-child patients with 
appropriate symptomatology.   
Ongoing Issues
During the last 25 years there has been an increase in
reported pertussis from <1 case to 9 cases per 100,000 
persons in 2004.  In the vaccine era, the cyclic peaks of 
reported pertussis still occur at 2- to 5- year intervals.  
This indicates that the agent is circulating in the 
population as in the prevaccine era.  If the circulation of 
B. pertussis were being impacted by immunization, one 
would expect an increase in the length of the inter-
epidemic period similar to the increase that occurred with 
measles in the 1970s and 1980s. 
The Dénouement 
It’s out there!  Pertussis is endemic and circulating even 
in countries such as the US where high vaccine coverage 
has been the case for several decades.  This cycle can be 
broken as the reservoir population becomes immune 
through preteen and adult Tdap immunization. 
• 	 Do not think of pertussis as solely a 

pediatric problem. 

• 	 Pertussis is solely a human disease.  There are no
reservoirs other than non-immune individuals.  
The main reservoir for the disease is adolescents 
and adults with waning immunity from childhood 
DTP/DTaP or infection.
• 	 Make sure pertussis is on your “radar screen” 
when considering the differential diagnosis of 
subacute or prolonged cough in adolescents and 
adults. 
• 	 Bordetella pertussis can be a deadly pathogen in 
young infants and children with small airways.  
Babies too young for vaccine and older infants 
without adequate humeral and cell-mediated 
immunity are at significant risk.  
• 	 Family members, caregivers and other close 
contacts with fading immunity are the persons 
most likely to infect at-risk infants and children. 
• 	 Pertussis can be quite problematic for 
adolescents and adults as well as children.  It 
probably accounts for up to 1/3 of the cases to 
prolonged cough in adolescents and adults 
• 	 Adolescent and adult disease may present quite 
differently than the ‘classic’ whooping cough we 
all learned of during our training.  They may have 
solely prolonged, paroxysmal coughs, no 
whooping, look and feel well between bouts of 
cough. 
• 	 Effective pediatric DTaP vaccine is widely
available and widely utilized.  It is safe. It is 
protective but immunity wanes in adolescence 
and adulthood  
• 	 Get your vaccination! 
• 	 Take the next clinical opportunity to immunize 
adolescent and adult patients.
• 	 Stress to adults the health benefits for the babies 
and children they love (their children, 
grandchildren, infant siblings) and/or their 
patients and clients.  
• 	 Mentally link pertussis with seasonal influenza to 
remember vaccine importance. Both are 
potentially deadly respiratory diseases, but are 
greatly impacted by vaccination!  
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Links for Pertussis Patient Education Resources 
CDC—Patient-friendly review of Pertussis:  
http://www.cdc.gov/Features/Pertussis/
CDC—Spanish version of above page: 
http://www.cdc.gov/spanish/especialesCDC/tosferina/
JAMA—one-page handout on pertussis: 
http://jama.ama-assn.org/cgi/reprint/304/8/922.pdf
Society of Teachers of Family Medicine Group on 
Immunization Education: 
http://www.immunizationed.org/
Tdap Vac on Facebook: 
http://www.facebook.com/pages/Tdap­
Vac/127068690654152
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Summary of Reportable Conditions – Jan 1, 2010 to Dec 15, 2010
Disease/Condition Confirmed Cases Probable Cases Total
Aseptic meningitis 103 0 103
Campylobacteriosis 330 0 330
Cryptosporidiosis 94 25 119
Cyclosporiasis 2 0 2 
Dengue Fever 5 10 15
Ehrlichiosis, chaffeensis 4 2 6 
Encephalitis, West Nile 1 0 1 
Giardiasis 141 0 141
Group A Streptococcus, invasive 99 0 99
Group B Streptococcus, invasive 53 0 53
Haemophilus influenzae, invasive 77 0 77
Hepatitis A, acute 20 0 20
Hepatitis B virus infection, Chronic 84 380 464
Hepatitis B, acute 58 0 58
Hepatitis C Virus Infection, past or present 3,075 24 3,099
Hepatitis C, acute 1 0 1 
Influenza, human isolates 36 0 36
Legionellosis 16 0 16
Leptospirosis 0 1 1 
Listeriosis 10 0 10 
Lyme disease 15 10 25
Malaria 6 0 6 
Mumps 4 0 4 
Neisseria meningitidis, invasive (Mening. disease) 12 0 12
Novel Influenza A Virus Infections 201 0 201 
Pertussis 323 68 391
Q fever 0 2 2 
Salmonellosis 1,676 5 1,681
Scombroid fish poisoning 1 0 1 
Shiga toxin-producing Escherichia coli (STEC) 13 1 14
Shigellosis 69 0 69
Spotted Fever Rickettsiosis 1 17 18 
Strep pneumoniae, invasive 478 0 478
Streptococcus pneumoniae, invasive disease (IPD) 2 0 2 
Tetanus 1 0 1 
Toxic-shock syndrome, staphylococcal 1 1 2 
Tuberculosis 147 0 147
Typhoid fever (Salmonella typhi) 1 0 1 
Varicella (Chickenpox) 82 1 83
Vibrio parahaemolyticus 5 0 5 
Vibrio spp., non-toxigenic, other or unspecified 9 0 9 
Vibrio vulnificus infection 1 0 1 
Yersiniosis 4 0 4 
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